Analysts predict that SAGE Therapeutics Inc (NASDAQ:SAGE) will announce earnings per share (EPS) of ($2.04) for the current quarter, Zacks reports. Zero analysts have made estimates for SAGE Therapeutics’ earnings. The lowest EPS estimate is ($2.35) and the highest is ($1.79). SAGE Therapeutics reported earnings of ($1.50) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 36%. The firm is scheduled to announce its next quarterly earnings results on Thursday, February 22nd.

According to Zacks, analysts expect that SAGE Therapeutics will report full-year earnings of ($7.42) per share for the current fiscal year, with EPS estimates ranging from ($7.73) to ($7.16). For the next year, analysts forecast that the company will post earnings of ($7.69) per share, with EPS estimates ranging from ($9.08) to ($6.43). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow SAGE Therapeutics.

SAGE Therapeutics (NASDAQ:SAGE) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.98) by $0.01. The business’s revenue for the quarter was up .0% compared to the same quarter last year.

Several research analysts recently commented on the stock. BMO Capital Markets restated an “outperform” rating and set a $112.00 target price (up previously from $85.67) on shares of SAGE Therapeutics in a report on Friday, November 17th. Needham & Company LLC increased their target price on shares of SAGE Therapeutics from $100.00 to $193.00 and gave the stock a “buy” rating in a report on Thursday, December 7th. Raymond James Financial increased their target price on shares of SAGE Therapeutics to $109.00 and gave the stock a “buy” rating in a report on Thursday, November 9th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $198.00 price target on shares of SAGE Therapeutics in a research report on Friday, December 8th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a $87.00 price target on shares of SAGE Therapeutics in a research report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $171.21.

Shares of SAGE Therapeutics (NASDAQ:SAGE) traded up $2.75 on Friday, reaching $169.46. 369,084 shares of the company traded hands, compared to its average volume of 602,377. SAGE Therapeutics has a fifty-two week low of $44.55 and a fifty-two week high of $180.83. The firm has a market capitalization of $6,960.00, a PE ratio of -24.67 and a beta of 3.05.

In other news, insider Stephen Kanes sold 44,000 shares of the stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $177.18, for a total value of $7,795,920.00. Following the transaction, the insider now directly owns 46,348 shares of the company’s stock, valued at $8,211,938.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Albert Robichaud sold 60,000 shares of the stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $159.43, for a total transaction of $9,565,800.00. Following the completion of the transaction, the insider now directly owns 152,759 shares in the company, valued at $24,354,367.37. The disclosure for this sale can be found here. Insiders have sold 314,247 shares of company stock worth $50,465,110 over the last ninety days. Insiders own 6.10% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. raised its position in shares of SAGE Therapeutics by 5.9% in the second quarter. BlackRock Inc. now owns 3,031,548 shares of the biopharmaceutical company’s stock valued at $241,431,000 after purchasing an additional 168,424 shares during the period. Vanguard Group Inc. raised its position in shares of SAGE Therapeutics by 2.2% in the second quarter. Vanguard Group Inc. now owns 2,749,954 shares of the biopharmaceutical company’s stock valued at $219,006,000 after purchasing an additional 58,679 shares during the period. Bank of New York Mellon Corp raised its position in shares of SAGE Therapeutics by 36.5% in the third quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock valued at $168,834,000 after purchasing an additional 724,494 shares during the period. State Street Corp raised its position in shares of SAGE Therapeutics by 7.7% in the second quarter. State Street Corp now owns 1,212,384 shares of the biopharmaceutical company’s stock valued at $96,558,000 after purchasing an additional 87,097 shares during the period. Finally, Oak Ridge Investments LLC raised its position in shares of SAGE Therapeutics by 0.9% in the third quarter. Oak Ridge Investments LLC now owns 736,709 shares of the biopharmaceutical company’s stock valued at $45,897,000 after purchasing an additional 6,835 shares during the period. 95.33% of the stock is currently owned by institutional investors.

WARNING: “SAGE Therapeutics Inc (SAGE) Expected to Post Earnings of -$2.04 Per Share” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://theolympiareport.com/2018/01/19/sage-therapeutics-inc-sage-expected-to-post-earnings-of-2-04-per-share.html.

About SAGE Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Get a free copy of the Zacks research report on SAGE Therapeutics (SAGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.